Barclays analyst Peter Warendorf initiated coverage of Progyny (PGNY) with an Overweight rating and $29 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny jumps after CEO Anevski buys $1.93M of common stock
- Progyny price target raised to $26 from $23 at Canaccord
- Carvana initiated, AT&T upgraded: Wall Street’s top analyst calls
- KeyBanc upgrades Progyny to Overweight on ’emerging’ catalysts
- Progyny upgraded to Overweight from Sector Weight at KeyBanc